Ocugenix Corporation
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration (NCT05904691) | Ocugenix Corporation | 2023-11-01 |
Track Ocugenix Corporation automatically
Every clearance here is in the API, with alerts when new ones post.